Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States

Table 4 Progression-free and overall survival of RET+ versus RET- cohorts from start of first-line therapy

Primary analysis, adjusted for covariates at the start of first line therapy
Outcome	N	Hazard Ratio, HR (95% confidence interval, CI)	P-value^*
Adjusted analyses
Progression-free survival (PFS)	5807	1.24 (0.86, 1.78)	0.25
Overall survival (OS)	5807	1.52 (0.95, 2.43)	0.08
PFS, Pembro + PC (KN-189 regimen)	674	1.07 (0.44, 2.61)	0.89
OS, Pembro + PC	674	1.54 (0.36–6.62)	0.56
Unadjusted analyses
PFS	5807	1.40 (0.99–2.00)	0.06
OS	5807	1.91 (1.22–3.00)	0.005
PFS, Pembro + PC	5807	1.01 (0.45–2.27)	0.98
OS, Pembro +PC	5807	1.92 (0.48–7.72)	0.36
Sensitivity analyses
PFS^a	5807	1.23 (0.86–1.78)	0.26
OS^a	5807	1.53 (0.96–2.44)	0.08
PFS^b	5807	1.27 (0.88–1.84)	0.20
OS^b	5807	1.56 (0.98–2.50)	0.06
PFS^c	5807	1.24 (0.86–1.78)	0.26
OS^c	5807	1.53 (0.95–2.44)	0.08
PFS^d	3615	1.10 (0.67–1.82)	0.71
OS^d	3615	1.47 (0.78–2.75)	0.23

^* Multivariable regression, adjusted for age, sex, race, practice type (academic or community), body weight, body mass index (BMI), stage at initial diagnosis, tumor histology, smoking status, microsatellite instability (MSI) status, genomic alterations, Eastern Cooperative Oncology Group (ECOG) performance status, PD-L1 expression (positive = > 1% staining versus negative), initial treatment regimen, and reported metastatic sites
^aCovariate of therapy received: Checkpoint inhibitor (ICI) monotherapy vs ICI combination therapy vs other treatments
^bCovariate of therapy received Checkpoint inhibitor (ICI) monotherapy vs ICI combination therapy vs biologic therapy vs other treatments
^cNot including therapy received as a covariate
^dExcluding missing variables
KN-189 first-line treatment with pembrolizumab (pembro) + pemetrexed + platinum (PC)

ISSN: 1471-2407